Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
Insmed (Nasdaq: INSM) will release its third-quarter 2025 financial results on Thursday, October 30, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed (Nasdaq: INSM) will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Management will host a conference call for investors at 8:00 a.m. ET the same day to discuss results and provide a business update.
Investors may dial (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189, or listen via live webcast at www.insmed.com. A replay will be available about one hour after the call through November 6, 2025 by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) with access code 7862189. The webcast will be archived for 90 days under the Investor Relations section of the company website.
Details
News Market Reaction – INSM
On Oct 15, the day this news came out, INSM closed 1.34% above the previous close.
Data tracked by StockTitan Argus for the Oct 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 30, 2025, to discuss financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (
A replay of the conference call will be accessible approximately 1 hour after its completion through November 6, 2025, by dialing (800) 770-2030 (
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two therapies approved to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2025-financial-results-conference-call-on-thursday-october-30-2025-302583906.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.